ADVANCING HUMAN HEALTH PRODUCTS. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus.

Transcription

1 >Galen in your country Galen in your country CONTACT < ADVANCING HUMAN HEALTH < Latest News Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus. Welcome To Galen Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. : Angina SEARCH Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus. CONTACT US Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec id elit non mi porta gravida at eget metus.

2 CONTACT // Galen Limited is a privately owned pharmaceutical sales and marketing company established in Our Founder Message From The MD Company Structure Locations Useful Links

3 CONTACT OUR FOUNDER // // OUR FOUNDER HISTORY MISSION STATEMENT AWARDS BOARD OF DIRECTORS LOCATIONS Galen Limited is a privately owned pharmaceutical sales and marketing company established in Galen promotes branded and generic prescription medicines in the United Kingdom and Ireland, and is poised to operate throughout the Big 5 European markets and then within the U.S.A. We currently have major brands in key therapeutic areas, particularly COPD, urology and pain management and will extend this to other therapeutic areas in the near future. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value, a major factor in the company's success to date. In April 2004 the company was acquired by the late Sir Allen McClay, the original founder of Galen and the owner of a group of pharmaceutical services companies under the umbrella of the Almac Group. The Almac Group has access to a wide variety of services, which ranges from drug discovery through to clinical trials management and commercial manufacture. Galen is now well placed to fulfil our vision of creating an international pharmaceutical company from its base in Northern Ireland. Key to achieving this vision will be developing our core values of innovation, quality, people and customer focus.

4 CONTACT MISSION STATEMENT // // MISSION STATEMENT HISTORY MISSION STATEMENT AWARDS BOARD OF DIRECTORS LOCATIONS At Galen, we strive to deliver innovation, quality and value to our customers and their patients. Nullam lacinia, massa in porta ornare, risus tellus aliquet ante, sit amet tempus arcu nibh a augue. Fusce quis nisl odio. Nulla tristique placerat vulputate. Duis bibendum nunc eu risus auctor, at sollicitudin magna ultrices. In vel quam id arcu imperdiet vulputate non non sapien. Curabitur gravida hendrerit commodo. Morbi fringilla sed nunc in pulvinar. Quisque in mi odio. Curabitur vitae neque pretium, facilisis quam non, convallis sapien. Donec et lobortis sapien, in suscipit purus. Aenean tincidunt, turpis molestie lacinia fringilla, quam magna semper turpis, vel sollicitudin libero enim ut arcu.

5 CONTACT COMPANY STRUCTURE // // BOARD OF DIRECTORS Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed faucibus urna eu turpis. HISTORY MISSION STATEMENT AWARDS BOARD OF DIRECTORS LOCATIONS John F. Kennedy Executive Member George W. Bush Executive Member Hillary R. Clinton Executive Member Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum. justo malesuada non. Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum. justo malesuada non. Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum. Ronald Reagan Abraham Lincoln Thomas Jefferson Executive Member Executive Member Executive Member justo malesuada non. Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum. justo malesuada non. Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum. justo malesuada non. Praesent posuere, dui quis egestas tristique, magna tellus mattis sem, vel dapibus dui velit quis ipsum.

6 CONTACT USEFUL LINKS // // USEFUL LINKS Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed faucibus urna eu turpis. HISTORY MISSION STATEMENT AWARDS BOARD OF DIRECTORS LOCATIONS Arthritis Research UK British Lung Foundation British Thoracic Society National Osteoporosis Society The Yellow Card Scheme Cystitis and Overactive Bladder Foundation British Heart Foundation

7 CONTACT // We develop safe, tested and quality pharamecuticals for a wide range of ailments and illnesses. TrustSaver Synera DaunoXome Calceos Zemtard Flotros Histofreezer Uracyst Laxido Saline Steripoules

8 CONTACT SYNERA // // SYNERA In order to guide you more accurately, please choose from one of the following options I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL Your choice will be remembered for the rest of your visit.

9 CONTACT SYNERA FOR PROFESSIONALS // // SYNERA // FOR PROFESSIONALS SYNERA Heat-Assisted Drug Delivery is Intended to Promote Faster Dermal Absorption of Anesthetics TRUST SAVER SYNERA FOR PROFESSIONALS Efficacy Safety How To Order Medical Enquiries Guides & Downloads Heat increases analgesic efficacy by up to 34% by enhancing the flux of lidocaine and tetracaine into the skin SYNERA increases skin temperature by up to approximately 5 C/9 F Total surface area of 50 cm2, of which 10 cm2 is active Familiar, adhesive bandage-like appearance Simple peel-and-stick application SYNERA should be used with caution in patients receiving class 1 antiarrhythmics and/or other local anesthetics, because the systemic toxic effects may be additive and potentially synergistic with lidocaine and tetracaine. Register For Updates DAUNOXOME CALCEOS FLOTROS HISTOFREEZER LAXIDO SALINE STERIPOULES URACYST ZEMTARD References: 1. SYNERA complete prescribing information. 2. Sawyer J, et al. Heated lidocaine/tetracaine patch (Synera, Rapydan ) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. BR J Anaesth 2009; 102: Masud S, et al. J Pain Symp Manage 2010; 40: Data on File. 5. Wallace MS et al. Evaluation of the depth and duration of anesthesia from heated lidocaine/ tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med 2010; 35: Curry SE, Finkel JC. Use of the Synera patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med Sep; 8(6): Sethna NF, Verghese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology Feb; 102(2): Berman B, Flores J, Pariser D, Pariser R, de Araujo T, Ramirez CC. Self-warming lidocaine/tetracaine patch effectively and safely induces local anesthesia during minor dermatologic procedures. Dermatol Surg Feb; 31(2): Hession PM, Joshi GP. Sedation not quite that simple. Anesthesiology Clin. 2010:

10 CONTACT SYNERA EFFICACY // // SYNERA // FOR PROFESSIONALS // EFFICACY SYNERA Provides Effective Local Dermal Analgesia Within Minutes TRUST SAVER SYNERA FOR PROFESSIONALS Efficacy Safety How To Order Medical Enquiries Guides & Downloads Register For Updates DAUNOXOME CALCEOS FLOTROS HISTOFREEZER LAXIDO SALINE STERIPOULES Patients are able to quickly feel the patch heating after application SYNERA produced local dermal analgesia to a depth of 7mm and analgesia continued to deepen for an additional hour after patch removal to a depth of >8mm5 URACYST ZEMTARD In clinical studies, the most common local reactions were erythema (7%), blanching (12%), and edema (12%); these reactions were generally mild, resolving spontaneously soon after treatment. EMLA is a registered trademark of Akorn, Incorporated. SYNERA Delivers Effective Local Anesthesia Within 20 Minutes of a Vascular Procedure 73% of SYNERA users reported pain relief compared to 31% of the placebo patch users, as measured by a 100 mm visual analog scale (VAS) (P=0.002) Median VAS scores were 5 and 28 for SYNERA and placebo treatments, respectively Proven Efficacy in Pediatric Populations SYNERA Brings Significant Pain Relief to Patients Prior to Minor Dermatological Procedures Important Safety Information For SYNERA (70 mg lidocaine/70 mg tetracaine) References: 1. SYNERA complete prescribing information. 2. Sawyer J, et al. Heated lidocaine/tetracaine patch (Synera, Rapydan ) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. BR J Anaesth 2009; 102: Masud S, et al. J Pain Symp Manage 2010; 40: Data on File. 5. Wallace MS et al. Evaluation of the depth and duration of anesthesia from heated lidocaine/ tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med 2010; 35: Curry SE, Finkel JC. Use of the Synera patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med Sep; 8(6): Sethna NF, Verghese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology Feb; 102(2): Berman B, Flores J, Pariser D, Pariser R, de Araujo T, Ramirez CC. Self-warming lidocaine/tetracaine patch effectively and safely induces local anesthesia during minor dermatologic procedures. Dermatol Surg Feb; 31(2): Hession PM, Joshi GP. Sedation not quite that simple. Anesthesiology Clin. 2010:

11 CONTACT SYNERA FOR PATIENTS // // SYNERA // FOR PATIENTS Good News! A Patch for the Pain of Needle-Related Procedures TRUST SAVER SYNERA FOR PATIENTS DAUNOXOME CALCEOS FLOTROS HISTOFREEZER LAXIDO SALINE STERIPOULES URACYST ZEMTARD While needle procedures are a necessary part of medical care, they can be a major source of pain. The good news is that it is possible to use a patch to reduce the pain associated with them in as little as 20 minutes! Your doctor is able to significantly relieve the pain of needle-related procedures in their patients. That s right. Patients no longer need to grin and bear it. Significant relief is available through a topical pain patch called SYNERA. What is SYNERA? SYNERA is a prescription pain patch that combines lidocaine, tetracaine, and heat to reduce pain associated with needle-related and dermatological procedures. The unique heating pod inside the patch gently warms the area where it is applied, helping the medicine penetrate the skin. Applied to the site of the procedure, it numbs the skin in as little as 20 minutes. The numbing medicine used in the patch is a combination of lidocaine and tetracaine. Latex-free Numbs the skin in as little as 20 minutes Proven to work safetly Proven Pain Relief and Safety SYNERA provides effective local pain relief to the skin within minutes. Proven pain relief and safety have been demonstrated in adults and children 3 years or older. Safety of Synera has been demonstrated in children of four months and older. In clinical studies, some skin reactions occurred at the application site, including redness, blanching, and swelling. These reactions were generally mild and went away by themselves. Allergic reactions such as hives, difficulty breathing, skin redness or swelling, and shock can occur. The doctor should be notified immediately if any of these or other symptoms are noticed. How SYNERA Is Used Apply Once the protective backing is removed, the SYNERA patch is applied by your healthcare provider to the skin where the needle is to be given. Warming Once exposed to the air, the self-warming system of SYNERA is activated, which is intended to enhance the delivery of medication through the skin. Experience Less Pain The patch is then peeled off the skin and properly disposed of prior to the procedure. References: 1. SYNERA complete prescribing information. 2. Sawyer J, et al. Heated lidocaine/tetracaine patch (Synera, Rapydan ) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. BR J Anaesth 2009; 102: Masud S, et al. J Pain Symp Manage 2010; 40: Data on File. 5. Wallace MS et al. Evaluation of the depth and duration of anesthesia from heated lidocaine/ tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med 2010; 35: Curry SE, Finkel JC. Use of the Synera patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med Sep; 8(6): Sethna NF, Verghese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology Feb; 102(2): Berman B, Flores J, Pariser D, Pariser R, de Araujo T, Ramirez CC. Self-warming lidocaine/tetracaine patch effectively and safely induces local anesthesia during minor dermatologic procedures. Dermatol Surg Feb; 31(2): Hession PM, Joshi GP. Sedation not quite that simple. Anesthesiology Clin. 2010:

12 CONTACT URACYST // // URACYST In order to guide you more accurately, please choose from one of the following options I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL Your choice will be remembered for the rest of your visit.

13 CONTACT URACYST FOR PROFESSIONALS // // URACYST // FOR PROFESSIONALS Effective relief from Painful Bladder Syndrome/Interstitial Cystitis TRUST SAVER SYNERA DAUNOXOME CALCEOS FLOTROS Uracyst is a 2% sterile solution of sodium chondroitin sulfate, which is available in 20ml vials (400mg of chondroitin sulfate per vial). Uracyst is indicated for the replenishment of the GAG (glycosaminoglycan) layer in the bladder, for patients with damaged or GAG deficient bladder epithelium. Although this will predominantly relate to Painful Bladder Syndrome/ Interstitial Cystitis (PBS/IC), a deficit in the bladder GAG layer has also been implicated in a number of other conditions, most notably other chronic forms of cystitis e.g.: Radiation cystitis Chronically-recurring bacterial cystitis PBS/IC is an enigmatic condition. The debate continues as to what to actually call the condition. But is the name of the condition really important at all? This website highlights some of the current thinking on the condition including: Nomenclature Causes Diagnosis Management Patients Clinical Phenotyping For the purpose of consistency, the condition is referred to as PBS/IC throughout this site. URACYST LOGO You are currently viewing information for healthcare professionals in the United Kingdom. CHANGE SETTINGS Downloads Directions For Use Uracyst Patient Guide Abbreviated Instructions for Use and Adverse Incident Reporting Management of PBS/IC PPT 1MB PMR-JUL Date of Preparation July 2012 HISTOFREEZER LAXIDO SALINE STERIPOULES URACYST FOR PROFESSIONALS Overview Efficacy Tolerability Volume Medical Enquiries Guides & Downloads Register For Updates ZEMTARD

14 CONTACT URACYST EFFICACY // // URACYST // FOR PROFESSIONALS // EFFICACY Over 21,000 instillations of Uracyst have been administered in Canada TRUST SAVER SYNERA DAUNOXOME CALCEOS FLOTROS HISTOFREEZER LAXIDO SALINE STERIPOULES URACYST FOR PROFESSIONALS Over 21,000 instillations of Uracyst have been administered in Canada and the product is now widely available in many countries across Europe as well as Canada. URACYST LOGO Efficacy Safety How To Order Medical Enquiries Guides & Downloads Register For Updates ZEMTARD The efficacy of Uracyst in the management of PBS/IC has been demonstrated in two main clinical studies, which you can find below. Study 1 - Nickel Et Al 2008 This real-life multicentre clinical practice study demonstrated that Uracyst is effective in relieving the symptoms of PBS/IC and reducing symptom and bother scores, thus demonstrating an improvement in patients quality of life. Fifty-three patients with long-standing, moderately severe PBS/IC received Uracyst once a week for 6 weeks, then once a month for 4 months. Every patient completed the study and received a total of ten instillations. Results For the primary outcome at 10 weeks (after 6 weekly treatments), the responder rate* was 47.2% and demonstrated clinical significance (see figure 1). Secondary efficacy endpoints assessed the percentage of responders after 24 weeks (10 treatments) and symptom and bother scores (see figures 1, 2 and 3). *A responder was indicated by a marked or moderate improvement on a sevenpoint patient Global Response Assessment (GRA) scale. You are currently viewing information for healthcare professionals in the United Kingdom. CHANGE SETTINGS Downloads Directions For Use Uracyst Patient Guide Abbreviated Instructions for Use and Adverse Incident Reporting Management of PBS/IC PPT 1MB PMR-JUL Date of Preparation July 2012 Response Rate Uracyst significantly improves patient quality of life Secondary endpoint measures also included differences from baseline in O Leary-Sant Symptom/ Problem Index scores over the course of the treatment, until the end of the study (24 weeks). O Leary-Sant Symptom Score decreased by a mean of five points (p<0.001 vs. baseline) or 37% reduction after 6 instillations (6.2 points, 43% after 10 instillations; p<0.001); O Leary-Sant Bother Score decreased by a mean of 4.3 points (p<0.001 vs. baseline) or 35% reduction after 6 instillations (5.7 points, 44% after 10 instillations; p<0.001). Uracyst significantly reduces the symptoms of PBS/IC Pain, urgency, and frequency scores (measured on a visual analogue scale) were also measured over the course of the treatment period. Significant reductions in pain, urgency and frequency (p<0.001) scores were reported after 6 and 10 instillations. Reductions in each symptom score compared to baseline are demonstrated on the graph above. Study 2 - Nickel et al 2009 References: 1. SYNERA complete prescribing information. 2. Sawyer J, et al. Heated lidocaine/tetracaine patch (Synera, Rapydan ) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. BR J Anaesth 2009; 102: Masud S, et al. J Pain Symp Manage 2010; 40: Data on File. 5. Wallace MS et al. Evaluation of the depth and duration of anesthesia from heated lidocaine/ tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med 2010; 35: Curry SE, Finkel JC. Use of the Synera patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med Sep; 8(6): Sethna NF, Verghese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology Feb; 102(2): Berman B, Flores J, Pariser D, Pariser R, de Araujo T, Ramirez CC. Self-warming lidocaine/tetracaine patch effectively and safely induces local anesthesia during minor dermatologic procedures. Dermatol Surg Feb; 31(2): Hession PM, Joshi GP. Sedation not quite that simple. Anesthesiology Clin. 2010:

15 CONTACT URACYST FOR PATIENTS // // URACYST // FOR PATIENTS TRUST SAVER SYNERA DAUNOXOME CALCEOS FLOTROS HISTOFREEZER LAXIDO Here you will find supportive advice and information about Painful Bladder Syndrome/ Interstitial Cystitis (PBS/IC) SALINE STERIPOULES URACYST FOR PATIENTS Efficacy Safety How To Order Medical Enquiries Guides & Downloads Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. URACYST LOGO Register For Updates ZEMTARD Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur? You are currently viewing information for healthcare professionals in the United Kingdom. CHANGE SETTINGS Downloads Directions For Use Procedure For Plantar Wart Treatment Abbreviated Instructions for Use and Adverse Incident Reporting

16 CONTACT HISTOFREEZER // // HISTOFREEZER In order to guide you more accurately, please choose from one of the following options I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL Your choice will be remembered for the rest of your visit.

17 CONTACT HISTOFREEZER FOR PROFESSIONALS // // HISTOFREEZER // FOR PROFESSIONALS Histofreezer is a portable cryosurgical device for freezing warts & other benign skin lesions TRUST SAVER SYNERA DAUNOXOME CALCEOS FLOTROS HISTOFREEZER Histofreezer is a portable cryosurgical device. The portable canister contains an environmentally friendly mix of dimethyl ether, propane and isobutane. How does Histofreezer work? Evaporation of the liquefied gas mixture draws heat from the surroundings. The applicator, which serves as a reservoir for the cryogen, reaches a temperature of -55oC within 15 seconds. Its action is based on the fact that different types of skin cells vary in their sensitivity to being frozen. Accordingly, epidermal keratinocytes are many times more sensitive to being frozen than the network of collagen fibres and fibroblasts in the underlying dermis. Melanocytes are also highly sensitive to being frozen. Necrosis of the keratinocytes can result in the development of a blister. Full recovery takes about 10 to 14 days, with new tissue growing inwards from the surrounding epidermis and the more deeply situated adnexa. If the dermis is undamaged by the treatment then healing will take place without scar formation. All forms of cryotherapy are based on this principle. Gentle On Patients Histofreezer works at -55oC giving*: Low levels of pain and discomfort Low risk of scarring and depigmentation Little or no damage to healthy tissue Histofreezer is usually well tolerated by patients * if used as per manufacturer's Directions for Use. HISTOFREEZER LOGO You are currently viewing information for healthcare professionals in the United Kingdom. CHANGE SETTINGS Downloads Directions For Use Procedure For Plantar Wart Treatment Abbreviated Instructions for Use and Adverse Incident Reporting PMR-JUL Date of Preparation July 2012 FOR PROFESSIONALS LAXIDO SALINE STERIPOULES URACYST ZEMTARD Tough On Warts Histofreezer is indicated for 9 benign skin lesions with resolution rates ranging from 86%-100%. Easy To Use To view the Histofreezer Directions for Use, please click here. Furthermore please read the Histofreezer Procedure For Plantar Wart Treatment document for instructions on how to treat plantar warts. Children under 4 years of age should not be treated with Histofreezer. For further information on Histofreezer including clinical papers and FAQs please visit The full Directions for Use should be consulted prior to use, particularly for recommended preparatory treatment, recommended freezing times for different lesions and for information on follow-up. Histofreezer Abbreviated Instructions for Use and Adverse Incident Reporting The information on this page is intended for use by healthcare professionals only. References: Sed et gravida magna, non pellentesque diam. Integer fermentum lobortis nisl, vitae mattis nunc dignissim elementum. Praesent sed tellus porta, dignissim ante sit amet, mollis lectus. Proin pulvinar massa non massa varius accumsan. Ut lacinia tristique dapibus. Proin vitae sapien at metus vestibulum fringilla. Donec vitae quam pellentesque, elementum erat at, imperdiet tellus. Vestibulum quam mi, tristique id enim id, facilisis ultrices dolor. Suspendisse potenti. Sed suscipit nisl et suscipit ultrices. Aliquam ultricies semper ipsum porta convallis. Phasellus tristique at risus sed imperdiet. Quisque faucibus porta lorem, tempor aliquam tellus posuere id. Aliquam quam urna, sagittis at arcu non, varius tincidunt ante. Integer semper luctus nisl, nec consequat enim vehicula non. Morbi enim justo, adipiscing quis mauris et, ultricies scelerisque arcu. Curabitur convallis odio eu libero pulvinar consectetur. Donec sed elit nisi. Sed auctor, lacus ac molestie laoreet, purus sem ullamcorper neque, vitae varius dui lorem non nisl. Morbi vel ligula sollicitudin ligula accumsan vulputate. Proin eu gravida neque. Aenean non ipsum et orci fringilla viverra hendrerit ac diam. Mauris ornare magna id justo placerat, porttitor semper purus condimentum. Integer vulputate sollicitudin mauris ac pellentesque.

18 CONTACT // We develop safe, tested and quality pharamecuticals for a wide range of ailments and illnesses. Angina Constipation Oncology & Haemotology Osteoperosis Overactive Bladder Painful Bladder Skin Lesions & Warts

19 CONTACT ANGINA // // ANGINA Angina is an uncomfortable or dull pain in the chest. ANGINA CONSTIPATION ONCOLOGY & HAEMOTOLOGY What causes it? Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart). Narrow coronary arteries reduce the blood flow to the heart muscle. OSTEOPEROSIS OVERACTIVE BLADDER PAINFUL BLADDER SKIN LESIONS & WARTS This is usually noticed at times when the heart muscle needs more blood supply, such as during exercise, extreme cold or after a heavy meal. What are the risk factors? You are at risk of angina if: You have a family history of atherosclerosis You have a high blood cholesterol level or high blood pressure You are a cigarette smoker and/or you have diabetes It can also be caused by obesity, stress or a lack of exercise. What are the risk factors? A squeezing or heavy pressing sensation on the chest which can spread to the arms, neck, jaw, back or stomach A constricting sensation in the throat Increased shortness of breath on exercise.

20 CONTACT Painful Bladder Syndrome / Interstitial Cystitis (PBS/IC) // // PAINFUL BLADDER SYNDROME / INTERSTITIAL CYSTITIS ANGINA CONSTIPATION ONCOLOGY & HAEMOTOLOGY OSTEOPEROSIS OVERACTIVE BLADDER PAINFUL BLADDER ABOUT PBS/IC LIVING WITH PBS/IC ABOUT THE BLADDER PBS/IC is a painful condition of the bladder, caused by the combination of two conditions SKIN LESIONS & WARTS Painful bladder syndrome (PBS) is described as pain over the pubic area, usually occurring as the bladder fills with urine. This is accompanied by other symptoms such as a need to visit the toilet more often than normal, both during the day and at night. Interstitial cystitis (IC) is inflammation of the bladder. This may be present for a long time, and can be difficult to treat. It may also be associated with other problems. What causes it? The exact cause of PBS/IC is still unknown, but there a number of different theories including: A weakness in the protective layer inside the bladder. This layer is called the glycosaminoglycan (GAG) layer and it protects the bladder from the urine. If it becomes leaky, the urine damages the bladder and can cause the symptoms of PBS/IC Infection with an unknown agent e.g. a slow-growing virus Production of a toxic substance in the urine Downloads Directions For Use Uracyst Patient Guide Abbreviated Instructions for Use and Adverse Incident Reporting Management of PBS/IC PPT 1MB Problems with the normal function of the pelvic floor An autoimmune disorder when the body attacks its own healthy cells by mistake Damage to the bladder itself or to the spinal cord in this region, for example as the result of an accident What are the symptoms? The typical symptoms of PBS/IC are pain in the bladder and surrounding pelvic area, urinary urgency (needing to go quickly), urinary frequency (going more often). Symptoms can improve or worsen at different times. Specific bladder pain associated with the condition typically worsens as the bladder fills and is temporarily relieved after urination. Pain may also radiate to the lower back and upper legs, as well as the vaginal area in women. Patients may experience this as a feeling of pressure, discomfort or heaviness, or as a burning or stabbing sensation. The pain can also be brought on or made worse by sexual intercourse in both men and women. Urinary frequency - An individual with a normal, healthy bladder might expect to urinate around seven or eight times per day. A person with PBS/IC may need to empty the bladder much more often (up to several times an hour), simply to relieve the pain. In severe cases, patients may need to urinate up to 60 times a day, that is two or three times every hour. Patients may also need to urinate several times during the night. Urinary urgency - Patients may feel a pressing need to go to the toilet due to increasing pain or discomfort that becomes impossible to tolerate. Some may also feel generally unwell and nauseous at the same time. How is it diagnosed? How is it treated?

21 CONTACT Living With PBS/IC // // LIVING WITH PBS/IC ANGINA CONSTIPATION ONCOLOGY & HAEMOTOLOGY OSTEOPEROSIS OVERACTIVE BLADDER PAINFUL BLADDER ABOUT PBS/IC LIVING WITH PBS/IC ABOUT THE BLADDER PBS/IC is more than just a set of symptoms. It may mean a change in lifestyle. SKIN LESIONS & WARTS For those with mild symptoms there may not be much change, but for those with severe symptoms it can have a serious effect on their quality of life. Due to the pain, increased frequency and urgency, patients may: Find it affects their social life because of their need to be near the toilet May have to change their job to allow easy access to a toilet Suffer physically and psychologically due to a lack of sleep Experience problems in their family life as the disease affects the whole family Experience difficulties with intimate relationships, unless they have a very understanding partner How does PBS/IC affect patients' lives? Downloads Directions For Use Uracyst Patient Guide Abbreviated Instructions for Use and Adverse Incident Reporting Management of PBS/IC PPT 1MB In June and July 2009, the Cystitis and Overactive Bladder (COB) Foundation conducted a survey on it's PBS/IC members. The survey was conducted by post and achieved 830 respondents, making it the largest ever survey of its kind in the UK. The survey found the following effects on patient's lives: 61% of respondents said that the worst thing about living with PBS/IC was the pain 94% of respondents have suffered from depression at some point due to their PBS/IC. Furthermore, nearly half of total respondents said they frequently suffer from depression due to their condition 82% said PBS/IC has an affect on their general mood 95% have suffered from sleep problems at some point due to their PBS/IC, with 69% regularly or severely suffering from sleep deprivation due to their condition 69% have experienced problems with intimacy with their partner due to their PBS/IC, with 51% of total respondents regularly or severely suffering intimacy problems 80% said PBS/IC has an effect on their social life and 84% said it affects their travel / holiday plans Self Help Measures Patient Stories

22 CONTACT CONTACT US // CONTACT US At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum Nullam lacinia, massa in porta ornare, risus tellus aliquet ante, sit amet tempus arcu nibh a augue. Fusce quis nisl odio. Nulla tristique placerat vulputate. Duis bibendum nunc eu risus auctor, at sollicitudin magna ultrices. Fields marked* are required Forename Surname * Adverse Event Reporting Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Galen Limited on +44 (0) and select the customer services options, or e- mail info@galen.co.uk. Medical information enquiries should also be directed to Galen Limited. Please input a valid address Telephone Nature of enquiry Report Adverse Event Comments* SUBMIT UK Galen Limited Seagoe Industrial Estate Craigavon BT63 5UA United Kingdom Telephone: +44 (0) Fax: +44 (0) customer.services@galen.co.uk USA Galen Limited Seagoe Industrial Estate Craigavon BT63 5UA United Kingdom Telephone: +44 (0) Fax: +44 (0) customer.services@galen.co.uk

23 CONTACT CONTACT US // CONTACT US Thank you for contacting us We will respond to you shortly UK Galen Limited Seagoe Industrial Estate Craigavon BT63 5UA United Kingdom Telephone: +44 (0) Fax: +44 (0) USA Galen Limited Seagoe Industrial Estate Craigavon BT63 5UA United Kingdom Telephone: +44 (0) Fax: +44 (0)

24 CONTACT SEARCH RESULTS FOR: ANGINA // SEARCH RESULTS : Angina SEARCH You are currently viewing search results from Galen US Showing 1-30 of 123 Results Sort By Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... CONTACT US PATCH Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... Angina Angina is caused by a lack of oxygen to the heart muscle. A lack of oxygen to the heart can be the result of coronary atherosclerosis (thickening of the arteries supplying blood to the heart)... Viewing 1-10 of XX results next > Sort By

25 You are now leaving the Galen Website. We are not responsible for the content of external websites. You will be automatically redirected.